As the depletion of Treg cells significantly reduces tumor burden [128,129,130], strategies targeting receptors (CCR4, CD25, CTLA-4, CCR8) preferentially expressed on tumor infiltrating Tregs [125,128,131] are currently being evaluated in clinical trials. Here, CCR8 is linked to neoplasm.